

A Review on SLN and NLC For Management of Fungal Infections.

ABSTRACT:

Fungal disease is an invasive, serious, and systemic topical infection that affects the mucous membranes, tissues, and skin of humans. Oral medicines, on the other hand, have significant side effects, making topical treatments a viable alternative. Many antifungal medications applied through the skin in various conventional forms (gels or creams) may cause skin redness, erythema, stinging, and burning sensations. A promising approach to overcome the limitation of conventional form is the use of Nanocarriers for the treatment of skin infections since it allows targeted drug delivery, enhanced skin permeability, and controlled release and hence offers a lower risk of side effects. During the last few decades, lipid nanoparticles (LNPs) such as solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) have gained a lot of attention. SLNs were designed to overcome the drawbacks of conventional colloidal carriers, such as emulsions, liposomes, and polymeric nanoparticles, by offering benefits such as a good release rate and drug targeting with high physical stability. NLCs are SLNs that have been modified (Second generation SLN) to improve stability and capacity loading. This review discusses the pathophysiology of the fungal diseases, the application of SLN and NLC, its method of preparation, Characterization, and an overview of clinical trials on SLN and NLC for the treatment of fungal infection.

KEYWORDS: *Fungal infection, solid lipid nanoparticles, Nanostructured lipid carriers, high-pressure homogenization.*

1.Introduction:

Fungal infections are becoming more common these days, especially among immunocompromised people. This increase in fungal infection is due to the association of immunodeficiency diseases or overuse of immunosuppressive drugs and may occur also during solid organ transplantation, stem cell transplantation, and neonatology. The coupling of pathogenic fungi has increased in fungal infection, whether superficial or systemic(1). Examples of fungal infection: Ringworm body (tinea corporis), Athlete's foot (tinea pedis) Jock itch (tinea cruris), Ringworm of the scalp (tinea capitis), Tinea versicolor. Cutaneous candidiasis, Onychomycosis (tinea unguium)(**Error! Reference source not found.**).

Fungal infections are divided into two types: superficial infections and systemic infections, which affect the entire body. Superficial infections affect the body's skin, eyes, hair, and nails, whereas systemic infections are associated with the human biological system. To treat these fungal infections solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) are used as a carrier for the antifungal drug, for effective treatment(**Error! Reference source not found.**).

In the year 1990, SLN were produced in laboratories as alternatives to liposomes, emulsions because of the biocompatibility of liquid lipids(**Error! Reference source not found.**). Drugs loaded with SLNs have shown advantages like reduced toxicity, increased loading capacity, chemical adaptability, the biodegradability of lipids, large-scale production capability(**Error! Reference source not found.**). NLC is the second generation of lipid nanoparticles. Unlike SLN, NLC's lipid matrix is made up of a mix of solid and liquid lipids, resulting in a reduced melting point of the lipid and at body temperature, the lipid matrix in the nanoparticles remains solid(**Error! Reference source not found.**). A surfactant or a combination of surfactants can also be used to stabilize NLC in aqueous dispersion. The inclusion of oil in the composition prevents the solid lipid from recrystallizing during storage, hence increasing the loading capacity, particularly for lipophilic substances (**Error! Reference source not found.**). The average size of SLN and NLC is in the nanoscale range, from 40 to 1000 nm depends on the composition lipid matrix (i.e., lipid and surfactant combination) and the manufacturing technique (3). The difference between SLN and NLC are shown in figure 1.






Figure 1: Schematic representation of SLN and NLC

2. Pathophysiology of Fungal Infection:

Fungi infections can be inherited from the environment, or they can be acquired from within the host in rare cases when they are part of the local flora. A frequent method is inhaling pathogenic conidia produced by molds growing in the microenvironment.(7). Some of these molds are found all over the world, while others are only found in places where the environment is conducive to their growth. The disease can only be acquired in the endemic region in the latter instance(**Error! Reference source not found.**). When environmental fungi are unintentionally injected across the epidermal barrier, they cause illness. Only a small percentage of fungi present in the environment are pathogenic(**Error! Reference source not found.**). Endogenous infections are restricted to a few yeasts, the most prevalent being *Candida albicans*. These yeasts can colonize by sticking to host cells and infiltrating deeper structures if given the chance (**Error! Reference source not found.**).

2.1 Pathogenesis:

In comparison to bacterial, viral, and parasitic infections, the pathogenic processes and virulence factors involved in fungal infections are less well understood (**Error! Reference source not found.**). The closest comparisons are to bacterial infections because of the enduring popularity of adherence to mucosal surfaces, severity, extracellular secretions, and contact with phagocytes(10, **Error! Reference source not found.**). The concepts covered fungal infections in general. The majority of fungi are opportunists, causing significant illness mainly in those who have weak immune systems. Only a few fungi are capable of infecting previously healthy people(**Error! Reference source not found.**).

2.2 Invasion:

Most effective infections must first pass through a surface barrier, such as the skin, mucous membrane, or respiratory epithelium. The mechanical fracture can introduce certain fungus and causes fungal infection (wound) (**Error! Reference source not found.**). *Sporothrix schenckii* infection, for example, usually occurs after a thorn puncture or other visible damage. To get past the upper airway defenses, (**Error! Reference source not found.**) infectious fungi that infect the lungs must produce conidia that are small enough to be inhaled. Arthroconidia of *Coccidioides immitis* (2-6 μ m), for example, can float in the air for a long time before reaching

the terminal bronchioles and causing pulmonary coccidioidomycosis (**Error! Reference source not found.**).

2.3 Trauma is associated with the traumatic injection:

Conidia that are small enough may be able to get through airway defenses. A dimorphic fungus in the environment goes through a metabolic shift similar to a heat shock reaction, changing its shape and development to a more invasive form, which is triggered by temperature and maybe other cues(**Error! Reference source not found.**). The invasion of the indigenous yeast *C. Albicans* directly via mucosal barriers is also associated with a morphologic alteration, the formation of hyphae. The cause of this transition is unknown, but the new form has the potential to enter and spread(**Error! Reference source not found.**). Extracellular enzymes (e.g., proteases, elastases) are associated with the advancing edge of *Candida's* hyphal form, as well as the invasive forms of a variety of dimorphic and other bacteria (**Error! Reference source not found.**).

2.4 Injury:

There has been little evidence that the extracellular products of opportunistic fungus or dimorphic pathogens harm the host directly during infection in the same way as bacterial toxins do but there is no evidence found for the presence of necrosis and infarction in the tissues of people infected with *Aspergillus* suggests toxicity such as infection, burns (**Error! Reference source not found.**). Exotoxins, also known as mycotoxins, are produced by certain fungi in the environment but not in humans. the fact that circulates widely throughout the body, the structural components of the cell do not have the same effects as Gram-negative bacteria's endotoxin. The circulating products of *Cryptococcus neoformans* have been proven to suppress immunological activities The damaging characteristics of delayed-type hypersensitivity (DTH) reactions as a result of the immune system's failure to remove the fungus appear to be the primary source of damage caused by fungal infections (**Error! Reference source not found.**) (**Error! Reference source not found.**).

3. Topical Antifungal:

Topical antifungal drug administration is likely the most effective method for combating major skin dermatophytes, as it ensures direct access to the target and a better retention rate. Topical administration also helps to avoid pre-systemic metabolism and reduces systemic toxicity. Various drugs, such as ketoconazole, itraconazole, and clotrimazole, are applied to the skin as a topical application. Table 2 depicts some of the marketed formulations available for the treatment of superficial fungal infections (22-24)




Figure 2: Different layers of skin

3.1 Antifungal medication resistance and biofilm formation:

A biofilm is a complex organic substance formed by a microbial community adhering to a substrate on its own. Biofilms provide a one-of-a-kind barrier to outside hazards. Cell adhesion is a suitable substrate, proliferation, matrix component synthesis, maturation, and dispersions are the biochemical phases that lead to the formation of fungal biofilms(25). Antifungal resistance is determined by the cell density inside the biofilm matrix, as well as the bacteria species. The most common fungus found in biofilms is *Candida albicans*. Other filamentous fungi, such as *Malassezia*, *Saccharomyces*, *Histoplasma*, and *Trichosporon*, have been implicated in the production of biofilms(26). Biofilm is thought to be critical to the survival of certain of these illnesses in hostile environments. Fungal biofilms are often studied using the microtiter plate paradigm. Morphogenetic alterations, growth circumstances, cell density, and the kind of extracellular matrix connections all influence biofilm development in *Candida albicans*(27,31). As the biofilm develops, the entire process is carefully regulated and managed by a sophisticated regulatory network. Recent research has found that liposomal versions of Amphotericin B exhibit exceptional antifungal effectiveness against *Candida albicans* resistant strains(28). Enzymatic hydrolysis of the enzyme cytosine permease, which is essential for cellular absorption of 5-fluorocytosine, releases the active medication 5-fluorouracil. When one or more of the aforementioned enzymes are weak, 5-FC resistance develops(29). Traditional topical formulations have several disadvantages, including limited permeability and significant adverse effects, making them unsuitable for long-term use. Due to the growing incidence of infections, azole resistance in non-*Candida Albicans* strains has become a major issue(30). Azole resistance in *Aspergillus fumigatus* has been associated with recurring sub-micron dosages and clinical exposure to mutant strains(31).

Several experimental antifungals are now being tested in human trials, with only a few showing results against azole-resistant species. These include drugs that target specific biochemical systems linked to drug resistance, such as ergosterol and β -glucan synthesis, making resistance easier to overcome(32). Because processes linked to fluconazole sensitivity, such as mutations in the *ERG11* gene, result in higher levels of lanosterol 14 α -demethylase, which is involved in azole metabolic deactivation, resistance to other azoles may develop (e.g., itraconazole, voriconazole)(33,34).

Table 1: Marketed formulations available for the treatment of superficial fungal infections.

Drug	Brand name	Dosage form	Manufacturer
Clotrimazole	Lotimin(1%)	Cream	Schering Schering_Plough Miles
	Gyne-Lotrimin(1%)	Cream	
	Mycelex_G(1%)	Cream	
Miconazole	Manistat_ermD(2%)	Cream	Pifzer Ortho_McNeil
	Micatin(2%)	Cream	
Ketoconazole	Xologel(2%)	Gel	Stiefel Labs Janssen
	Nizoral(2%)	Cream	
Econazole	Spectazole(1%)	Cream	Ortho Macrochem- corporation
	Econail(5%)	Nail lacquer	
Sertaconazole	Ertaczo(2%)	Cream	Ortho Neutrogena
Ciclopirox	Laprox(0.77%)	Cream	Hoechst- marrion-Roussel Aventis pharma
	Laprox(0.77%)	Gel	
Terbinafine	Lamisil(1%)	Cream	Merz pharmaceuticals
Fluconazole	Flucomet(0.3%)	Eye drops	Sun Torrent FDC
	Syscan(0.3%)	Eye drops	
	Zocon(0.3%)	Eye drops	
Natamycin	Natacyn(5%)	Ophthalmic Suspension	Alcon
Ciclopirox amine	Only(8%)	Nail lacquer	Cipla Dermik Protech biosystem
	Penlac(8%)	Nail lacquer	
	Nailon(8%)	Nail lacquer	
Amorolfine	Loceryl(5%)	Nail lacquer	Roche lab


4. Lipid Nanoparticles for the treatment of Fungal Infection:

Particle size, surface charge, and lipophilicity all have a role in determining the depth of penetration into various skin layers. The smaller size of lipid particles allows for closer interaction with the stratum corneum, allowing for better medication penetration and regulated release.(31,35) Because of their ability to alter and improve the pharmacokinetic and pharmacodynamic properties of drugs, nanoparticles have been used in pharmaceutical formulations. This is due to their capacity to improve drug solubility and stability, allow for controlled release, and show biocompatibility with tissues and cells, all of which contribute to an overall increase in therapeutic efficiency. As a result, developing novel biopharmaceutical systems, particularly nanoparticulate carriers, is an effective technique for improving the therapeutic efficacy, safety, and compliance of antifungal agents (36,37). Table 2 depicts some of the lipid based nanoparticle formulations for antifungal drug delivery.

Table 2: Lipid Nanoparticles containing antifungal drugs marketed for topical application

DRUG	NOVEL FORMULATION	FINDINGS
Miconazole	Liposome, niosome SLN.	The prepared formulation has good, enhanced permeation properties to the skin(6).
Fluconazole	Liposomes, Niosome, SLN&NLC	SLN formulation shows better localization in dermal and it is sustained released over a day. (25) NLC prepared formulation showed better retention time over the skin and effective targeting properties compared to SLN.(Error! Reference source not found.)
Clotrimazole	SLNs and NLCs	NLC showed increased drug entrapment compared to SLNs. (61)
Ketoconazole	SLN and NLC	SLN were not stable while NLC were stable while exposed to light (72)

Global market trend of Anti microbials.



Anti fungal agents contribute for only 15%. Due to poor solubility and poor permeability issues faced by active pharmaceutical ingredient .so novel drug delivery system is needed in this field to overcome disadvantages.

Approches;
Use of SLN and NLC.
Nano emulsion.
Liposomes,Niosomes. Etc.

Figure 3: Descriptive analysis of the use of antimicrobials

5. Methods of preparation of NLC and SLN:

5.1 High-pressure homogenization:

The SLN and NLC for preparing approach is high-pressure homogenization. This strategy's advantages extend beyond its quick construction time. The strategy likewise permits lab-scale preparation to be effortlessly translated to huge scope creation. Furthermore, the evasion of natural solvents, yielding normal molecule size in the submicron area, and because of the wide range of homogenizer brands and types available at a reasonable price, is a widely used method in many businesses. (38). In any event, because it is a high-energy cycle, it raises the temperature, which is incompatible with heat-sensitive apparatus. This approach entails applying strong pressure to a very small hole (a couple of microns wide). Particles are reduced to submicron size due to high shear pressure and cavitation powers. At both high and low temperatures can be homogenized in high-pressure homogenization for SLN and NLC can be achieved (hot and cold homogenization, individually). In any case, keep in mind that the drug should be dissolved or scattered at a temperature of 5°C above its melting point (39).

The entire interaction is carried out at temperatures over the lipid's liquefying point in hot homogenization. Fast mixing produces a pre-emulsion of the drug layered lipid is softened and the fluid is emulsified (5-10°C above lipid Melting point) (for example Ultra-Turrax). The heated pre-emulsion is later homogenized at a controlled temperature using a high-pressure homogenizer. When the pre-emulsion lipid fixation is in the range of 5-10%, a single homogenization cycle is adequate to produce a hot emulsion with molecule sizes in the range of 250–300 nm. (40). Finally, obtained nano emulsion is cooled to room temperature and recrystallizes, forming SLN and NLC. Emulsion fixation levels of 40% or above can also be homogenized. NLC cannot be formed with lipid contents greater than 30%; instead, unusually considered SLN features must be employed. Regardless, the emulsion lipid fixation will dictate the number of cycles, as the energy required to shear the lipid mass is proportional to its focus in the detail. However, because molecule dynamic energy increases favor mixture, increased order of homogenization cycles usually results in larger molecules(41). In most cases, three homogenization cycles are recorded in the literature. Advantages: Hot homogenization can be employed in any situation for temperature-sensitive combinations because the hour of exposure to higher temperatures is usually brief. Disadvantages:

Especially for temperature-sensitive mixes and hydrophilic mixtures, which can transition from the lipid to the aqueous phase when heated to a high temperature (39, 40).

5.2 Cold homogenization:

This approach is same as that of hot homogenization technique which comprise of dispersion or dissolving or solubilization of the drug in the melted lipid. Then the drug lipid mixture is rapidly solidified either with the help of liquid nitrogen or dry ice. The drug-loaded solid lipid is milled by using a roller mill or ball mill to a micron size range of 50-micron to 100 micron and further microparticles are dispersed in chilled emulsifier solution to obtain a pre-suspension. Then this pre-suspension is subjected to high-pressure homogenization at room or below room temperature, where the cavitation force is strong enough to break the microparticles to SLN and NLC (82,83).

5.3 Microemulsion technique:

The lipid phase is melted, and the aqueous phase (which contains surfactant) is heated to the same temperature as the lipid (or lipid mix). The lipid phase of the microemulsion is completed by gently mixing in the aqueous solution to form the microemulsion. To prepare lipid nanoparticles, the microemulsion is added to cold water (2-10°C). Finally, the prepared nanoparticle is lyophilized after being rinsed with distilled water, filtered (to eliminate bigger particles), and rinsed again to remove excess water. The limitations, by the way, include the requirement for relatively large surfactant groups, as well as the drug leakage from the molecule suspension caused by the microemulsion being emptied into the water, resulting in a suspension with an exceedingly low drug loading (41). **Advantages: It is easily scalable from lab scale studies to pilot plant studies.** **Disadvantages: Toxicological problems may cause the complications.**

5.4 Emulsification by solvent evaporation:

The lipid is dissolved in a water-insoluble organic solvent and subsequently emulsified by the aqueous phase in this method. The solvent evaporated at low pressure, allowing lipid precipitation and nanoparticle dispersion in aqueous solutions to occur (39). This is a fully heat-free process that can make nanoparticles are reduced to 100 nm depending on the employed components. Using an organic solvent, on the other hand, has the drawback of leaving hazardous residues in the sample(39).

5.5 Solvent injection:

The lipid is liquified in a water-miscible solvent before being quickly injected with a micro-injection needle into a stirred surfactant-containing aqueous phase(44). When it comes to generating lipid nanoparticles, the process is straightforward to apply,

versatile, and effective. However, utilizing an organic solvent has several drawbacks(42) . Advantages: This technique does not require low or high temperatures. No need for pH modification, ultrasonication, homogenization, or pressure variations (43).

5.6 Phase Inversion:

Magnetic stirring of the formulation contents (lipid matrix, drug, water, and surfactant) and three different temperature cycles (85-60-85-60-85°C) are used in this method to achieve the inversion process(43). The combination is then given a cold distilled water thermal shock, which causes lipid nanoparticles to develop. This process requires no organic solvents and only a brief heating duration. However, it is a lengthy procedure with numerous steps(43).

5.7 Membrane contraction technique:

This method was developed to mass-produce lipid nanoparticles. In the molten lipid holding matrix the drug is forced into an aqueous phase containing surfactant that is kept at lipid melting temperature (usually with a pore diameter of 0.05 m) through a porous membrane(39). The lipid creates minute droplets as it travels through the holes, which precipitate as lipid nanoparticles then the preparation is cooled to room temperature. The strategy is straightforward scalable, and the change in particle size is as simple as switching between membranes with varying pore diameters(44).

Advantages: SLN and NLC size can be controlled to an appropriate size (52).

Disadvantages: The main drawbacks of this method are potential metal contaminations and physical instability (47).

6 Physicochemical Characterization of SLN and NLC:

The physicochemical characteristics of NLC are critical for quality assurance and security to investigate the structure and versatility, various strategies were used, including particle size analysis, zeta potential (ZP), transmission electron microscopy, differential scanning calorimetry (DSC), X-Ray diffraction (XRD), laser diffraction, and field-flow fractionation. These processes reveal the formulation's physical and chemical stability; the surface charge, in general, determines whether or not the particles will flocculate (45).

6.1 Particle size:

The physical stability of dispersion is dependent on particle size, and as particle size drops, the surface area rises, particle size is a significant parameter in creating control and quality (46). PCS (Photon Correlation Spectroscopy) is based on laser light diffraction and may be used to examine particles with diameters ranging from 200 nm to 1 μ m. Rayleigh's theory states that the scattering intensity of particles smaller than 200 nm corresponds to the sixth power of the particle dimension (48).

6.2 Zeta potential:

The electric potential of a particle in suspension is denoted by ZP. It's a metric that may be used to determine the physical stability of colloidal dispersions. The surface charge generates a potential surrounding the particle that is greatest at the surface and diminishes as the particle separates from the medium (**Error! Reference source not found.**). The ZP may be calculated by measuring the particle speed in an electrical field (electrophoresis measurement). This procedure may be used to determine the form of the particles that have been created as well as their molecular size (**Error! Reference source not found.**). On a sample holder, aqueous Nano lipid carrier dispersions can be applied and dispersed (thin carbon film). The samples are placed inside the magnifying lens' vacuum section, and the air is sucked out of the chamber. Light emission is produced by an electron cannon located at the top of the column. The electrons emitted by the light travel through the lens, which focuses them into a small point and scans the material row by row. The electrons are then collected, and the signals are delivered to an amplifier (**Error! Reference source not found.**).

6.3 Differential scanning calorimetry:

DSC is a commonly used method to get information on a formulation's physical and energetic characteristics. It calculates the heat loss or gains as a function of temperature due to physical or chemical changes inside the sample (**Error! Reference source not found.**). The

degree of crystallinity of the particle scattering is determined by using DSC on powder. The rate of crystallinity is measured by DSC by comparing the bulk material's liquefying enthalpy/g to the scattering's softening enthalpy (**Error! Reference source not found.**).

6.4 Atomic force microscopy:

Atomic force microscopy (AFM) is an excellent tool for evaluating extremely small morphological and surface features. AFM uses a very tiny sharp-tipped probe at the free end of a cantilever that is driven with interatomic repulsion or attraction interactions between the tip and the specimen's surface, rather than photons or electrons (**Error! Reference source not found.**). While electron microscopy is still commonly used, AFM has various advantages, including real-time quantitative data collection in three dimensions, quick sample preparation times, flexibility in working settings, and effective nanoscale magnifications (**Error! Reference source not found.**).

6.5 In vitro drug release:

To measure the rate of drug release content from drug products, in-vitro release uses well-established Franz diffusion cells. It entails the administration of a drug to a membrane that separates the donor and receiver chambers (synthetic membrane, excised animal skin, or excised human skin) (**Error! Reference source not found.**). In vivo, the receiver chamber duplicates sink conditions. The rate of delivery obtained in these investigations is thought to be comparable to the condition in vivo. The approach has been frequently employed in drug discovery studies to assess formulations and to understand cutaneous drug transport mechanisms. In a systematic flow, the controlled release of drugs from lipid nanoparticles can result in a longer half-life and delayed enzymatic attack. The temperature at which NLCs are manufactured affects the drug release behaviour (**Error! Reference source not found.**).

7. Lipid nanoparticles for topical anti-fungal drug delivery:

With a surface area of about 2m², the skin is one of the body's major organs. It has three layers: a thin epidermis on the exterior, a thicker middle layer dermis, and the thickest hypodermis on the interior. It conducts a variety of important functions. The stratum corneum, the epidermis' outermost layer, is made up of keratinized and dead cells(58,59). Because of their high lipid content, pharmaceuticals with a greater drug payload and delayed, controlled drug release should be able to pass through it, notably azole drugs (60). SLNs containing clotrimazole and a co-surfactant (PEG 600) were made utilizing a heated high-pressure homogenization method exhibit excellent performance and high encapsulation efficiency of up to 70% for Ketoconazole (**Error! Reference source not found.**). In determining the efficacy of encapsulated medicines, however, the type of lipids, surfactants, concentration, and preparation technique are all critical considerations. Due to the highly organized crystalline structure of the lipid matrix, which leaves limited space for therapeutic molecules, lipid nanoparticles containing high molecular weight fatty alcohols and straight-chain primary alcohols exhibit low drug loading capacity and delayed-release behavior. Low melting point lipids, such as triglycerides, partial glycerides, and amphiphilic lipids, on the other hand, are regarded to be suitable for SLNs because they allow for higher drug loading, improved skin penetration, and less antifungal drug leakage. Based on qualified benefits, SLN is observed to be a feasible formulation for topical delivery of antifungal agents (60,61,62).

Souto et al developed SLNs and NLCs containing clotrimazole for topical delivery. SLN with occlusive features has been produced as carriers that allow continuous drug release behavior over 10 hours, making them appropriate for topical applications (**Error! Reference source not found.**). SLNs and NLCs protect the encapsulated drug in formulation from photodegradation, assuring its stability, and have shown antifungal efficacy against *Candida albicans* comparable to the commercial product (62,63). Sanna et al found that SLN formulations increased encapsulated econazole nitrate penetration beyond the stratum corneum's impermeable after 1 hour and had better when compared to reference gels, econazole nitrate penetrated deeper layers of skin after 3 hours. (64) Passerini et al. compared the efficacy of econazole nitrate loaded SLNs to solid lipid microparticles with similar formulations in terms of treatment efficacy with characteristics. When compared to commercial gel formulations, SLN preparations demonstrated significantly higher miconazole nitrate skin permeability (**Error! Reference source not found.**). The targeted effect of SLN preparations is also significantly greater. Cassano et al have revealed that *Candida albicans*-causes vaginal yeast infections, SLNs containing ketoconazole (KCZ) and clotrimazole (CLT) prepared with PEG-40 stearate and PEG-40 stearate acrylate are effective. Nanocarriers can penetrate the skin layers and transport topical medicines. SLN, liposomes, niosome, and microemulsion are examples of novel topical formulation techniques are microemulsion, Nano emulsion, etc. (**Error! Reference source not found.**).

The therapeutic agent is incorporated inside a lipid core matrix in these nano-lipid carriers. High homogenization or microemulsion preparation methods can be used to formulate SLN (**Error! Reference source not found.**). SLNs are emulsion-free SLNs with solid lipids as the oil phase. SLNs have low toxicity (the lipids utilized are biologically identical), making them biocompatible. The tiny size of lipid particles permits closer interaction with the stratum corneum, resulting in better permeation of the and regulated release (**Error! Reference source not found.**,69). Their composition forms a coating on the skin, preventing water from evaporating. As a consequence, the skin is kept moisturized and the barrier function is preserved. Because the lipid nanoparticles are spherical and have great lubricating properties, which helps to minimize skin irritation and allergies. They have more drug entrapment capacity and well-modulated release kinetics. Encapsulation protects the active components from degradation (67-69). However, SLNs have a few drawbacks, such as a restricted number of drugs and a lipid SLN grown to a large amount employing cationic lipids. Disruption of endosomal membranes, formation of DNA complexes, and increased cell permeability are all recognized methods through which cationic lipid modulates antifungal action. Debora and colleagues have proposed that cationic lipids, such as dioctadecyl dimethylammonium bromide (DODAB) and hexadecyltrimethylammonium bromide (CTAB), had strong antifungal action against *Candida albicans* (**Error! Reference source not found.**). Nonetheless, over a therapeutic dose, cationic lipids cause local toxicity. Furthermore, the size of SLNs influenced the result of cutaneous mycosis therapy. In a recent study, Zahra et al evaluated the impact of SLN size on skin penetration. The results showed that SLNs in the 50–200 nm range readily penetrate the cutaneous layer, whereas sizes larger than 200 nm accumulated in the dermis, so these formulations are used ineffective treatment for fungal infection (**Error! Reference source not found.**). Despite their benefits, SLNs have a few drawbacks, such as limited drug-loading and irregular drug release. NLCs are second-generation lipid nanoparticles consisting of a blend of solid and liquid lipids capable of holding a wide range of drugs (**Error! Reference source not found.**). In research comparing the encapsulation performance of NLC and SLNs for Ketoconazole, it was discovered that SLN and NLC had 62.1 and 70.3 percent encapsulation, respectively. Furthermore, as compared to SLNs, NLC has successfully enhanced Ketoconazole's light stability (72). Furthermore, NLC has superior drug solubility and skin permeability than SLNs due to lower fatty acid triglycerides. In their investigation, Gratieri et al. found that NLC had higher voriconazole encapsulation efficiencies and improved cutaneous delivery when compared to SLNs and plain drugs (73). Recently, topical gels based on lipid nano-carriers were developed to alleviate some of the drawbacks of lipid nano-carriers, such as poor application site retention, limited drug loading, unstable during long-term storage, and the likelihood of drug ejection. El-Housin et al., have investigated the therapeutic potential of Fluconazole-loaded SLNs Cremophor RH40 and Poloxamer 407 topical gel in the treatment of Pityriasis Versicolor. Entrapment efficiency

ranged from 55.49 percent to 83.04 percent, according to the findings. Clinical trials revealed a 1.4-fold better clinical response when compared to commercial cream. Although nano-lipid preparations have been shown to increase therapeutic effectiveness and safety in the treatment of essential fungal illnesses (**Error! Reference source not found.**4)

Some of Patents for antifungal drug containing lipid nanoparticle given in Table 4

UNDER PEER REVIEW

Table 3: Recent advances in Lipid nanoparticles of anti-fungal agents

Antifungal drugs (SLN and NLC)	Lipids	Mode of action	Method of preparation	Diseases	Findings	Reference
Fluconazole and FLZ-SLNs	Compritol 888 ATO Precirol ATO5	It acts by preventing production of vital elements in the fungal membrane as ergosterol by inhibiting the fungal cytochrome P-450 enzyme. This inhibition action on cytochrome P-450 enzymes was found to be greater in fungal species in contrast to mammalian enzyme, which improve the safety profile of triazoles	high shear homogenization and ultrasonication method	pityriasis versicolor	superior significant fast therapeutic index in treatment over commercially available CandistanV R cream.	(73)
Ketoconazole-SLN	Tripalmitin	inhibits the transformation of blastospores to invasive mycelial forms	hot homogenization coupled with the ultrasonication method	fungal infections	Improved Bioavailability, enhanced antifungal activity	(74)
clotrimazole (CLZ) and alpha-lipoic acid (ALA)-SLN	dimethyldioctadecylammonium bromide	CLZ antifungal activity is related to its capability to interfere with the biosynthesis of ergosterol, the major component of the fungal cytoplasmic membrane, with the consequent depletion of ergosterol and its replacement with the aberrant sterol species, 14-a-methylsterol, thus disturbing the membrane permeability and fluidity	phase inversion procedure	Candida albicans mycosis	potential synergistic treatment of topical infection	(75)
Fluconazole-loaded solid lipid nanoparticles	glyceryl monostearate	NA	hot homogenization via an ultrasonic probe	oral candidiasis	local and systemic effect of FZ-loaded SLNs of candidiasis through the buccal mucosa.	(76)
Itraconazole - NLC	Tricaprylin and Compritol 888	inhibition of the P450-dependent lanosterol C14 α - demethylase enzyme, which is an essential step for the conversion of lanosterol to ergosterol in the fungus, leading to the disruption of permeability and function of the plasma membrane		Sporotrichosis	improved cutaneous targeting of the drug, demonstrated antifungal efficacy	(77)

econazole-loaded nanostructured lipid carriers	Glycerol monostearate, Capmul MCM	suppressing the growth of dermatophytes in stratum corneum as well as in epidermis	ultrasonication emulsion technique	dermatophytes	enhanced antifungal activity against dermatophytes	(78)
Luliconazole - NLC	Palmitic acid, Oleic acid	inhibiting 14-alpha-lanosterol demethylase (membrane protein of CYP51 class in the cytochrome P450 superfamily of enzymes involved in ergosterol biosynthesis) in the fungal cell wall	hot melt emulsification technique followed by probe sonication	Superficial Tinea infections	Enhanced antifungal activity of Luliconazole NLC compared to cream form	(79)
Fluconazole- NLC	stearic acid, oleic acid	NA	emulsification/sonication technique	oral candidiasis	improved anti-candidiasis activity	(80)
Luliconazole- NLC	Compritol 888 ATO, Labrafil M 2125	NA	hot emulsification followed by ultrasonication technique	fungal infections	Enhanced antifungal activity	(81)

Table 4: Patents on lipid nanoparticles for fungal infection

IN202117035651	Targeted nanoparticles and their uses related to fungal infections
AU2021105626	Development and evaluation of luliconazole loaded solid lipid nanoparticles-based gel for topical application
IN1813/DEL/2011	"A novel solid lipid nanoparticle formulation"
WO2020028916	Amphotericin loaded pegylated lipid nanoparticles and methods of use

8. Status of Lipid nanoparticles for fungal infection in clinical trials:

Nanoparticles are becoming more popular as a result of medical applications such as diagnosis and therapy and with an increased number of nanomedicines currently in clinical trials. The key

advantages of nanoparticles are their ability to control drug release, distribution, and delivery to a specific site in order to reduce toxicity by inhibiting drug access into other parts of the body. Only a few clinical trials involving lipid nanoparticles for the treatment of the fungal infection are discussed.

Clinical Assessment of Oxiconazole Nitrate Solid Lipid Nanoparticles Loaded Gel (ClinicalTrials.gov Identifier: NCT03823040) was conducted by Minia University on Active Comparator: Tinox® group the male patients (12 to 43 years old) including 5 cases tinea pedis, 9 tinea versicolor and treated with oxiconazole nitrate cream 1% and Experimental: Oxiconazole nitrate SLNs loaded gel group 13 males and one female (17 to 50 years old) including 3 cases tinea pedis, 8 tinea versicolor, 3 tinea circinate and treated with oxiconazole nitrate SLNs loaded gel. Both the group treatment was performed by rubbing the gel twice daily for two/ four weeks according to different types of tinea. phase I study for the Oxiconazole Nitrate Solid Lipid Nanoparticles Loaded Gel is completed(84). The researchers conducted a clinical investigation on over 30 patients with Pityriasis versicolor to test FLZ-SLNs topical gels, the results of which were compared to Candistan cream. In this study, each patient was followed up by a clinical and mycological assessment every week during therapy to examine the clinical efficacy and safety of various treatment regimens. The authors reported that the formulation appeared to be faster and more effective than topical Candistane. (73)

Conclusion:

Fungal infections have become a major public health concern due to their high prevalence. The use of a nanodrug delivery system to enhance the treatment effectiveness, safety, and compliance of antifungal medicines is an excellent technique to overcome the limitations of conventional forms such as cream, gel. This system has shown promising results in terms of increased water solubility, efficiency, and stability of antifungal agents. When compared to other colloidal carriers, SLNs is a complex system with evident advantages and limitations. NLCs were developed to overcome the stability and drug leakage issues of the SLN. Because its disordered crystal matrix prevents drug expulsion resulting in high drug entrapment efficiency. Nanotechnology enables the development of formulations that increase not only the treatment's effectiveness but also the patient's quality of life by lowering side effects, particularly during long-term therapy. Even though using lipid nanoparticles for topical administration is a very promising and appealing application field, more research is required to understand the mechanism of penetration and interaction of nanoparticles.

Ethical Approval:

As per international standard or university standard ethical approval has been collected and preserved by the authors.

Future perspective.

Skincare products infused with nanotechnology are quickly spreading over the world and have proven to be very beneficial in the treatment of fungal skin diseases. Because there are no precise

restrictions in place at the moment, these medications are fast proliferating in the personal care industry. However, there are environmental and safety problems. there are several adverse effects that need to be addressed. as a result, there is an urgent need for harmonized rules and guidelines for the use of nanoparticles.

COMPETING INTERESTS DISCLAIMER:

Authors have declared that no competing interests exist. The products used for this research are commonly and predominantly use products in our area of research and country. There is absolutely no conflict of interest between the authors and producers of the products because we do not intend to use these products as an avenue for any litigation but for the advancement of knowledge. Also, the research was not funded by the producing company rather it was funded by personal efforts of the authors.

References:

1. Walker GM, White NA. Introduction to fungal physiology. *Fungi: biology and applications*. 2017 Nov 22:1-35.
2. Kumar L, Verma S, Bhardwaj A, Vaidya S, Vaidya B. Eradication of superficial fungal infections by conventional and novel approaches: a comprehensive review. *Artificial cells, nanomedicine, and biotechnology*. 2014 Feb 1;42(1):32-46.
3. Naseri N, Valizadeh H, Zakeri-Milani P. Solid lipid nanoparticles and nanostructured lipid carriers: structure, preparation and application. *Advanced pharmaceutical bulletin*. 2015 Sep;5(3):305.
4. Low CY, Rotstein C. Emerging fungal infections in immunocompromised patients. *F1000 medicine reports*. 2011;3.
5. Müller RH, Alexiev U, Sinambela P, Keck CM. Nanostructured lipid carriers (NLC): The second generation of solid lipid nanoparticles. *Percutaneous Penetration Enhancers Chemical Methods in Penetration Enhancement: Nanocarriers*. 2016 Jan 1;161–85.
6. Mukherjee S, Ray S, Thakur RS. Solid lipid nanoparticles: A modern formulation approach in drug delivery system. *Indian Journal of Pharmaceutical Sciences*. 2009 Feb 1;71(4):349–58.
7. Kobayashi GS. Disease mechanisms of fungi. *Medical Microbiology*. 4th edition. 1996.
8. Konopka JB, Casadevall A, Taylor JW, Heitman J, Cowen L. One health: fungal pathogens of humans, animals, and plants.
9. Köhler JR, Casadevall A, Perfect J. The spectrum of fungi that infects humans. *Cold Spring Harbor perspectives in medicine*. 2015 Jan 1;5(1):a019273.

10. Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P. Introduction to pathogens. In *Molecular Biology of the Cell*. 4th edition 2002. Garland Science.
11. Krüger W, Vielreicher S, Kapitan M, Jacobsen ID, Niemiec MJ. Fungal-bacterial interactions in health and disease. *Pathogens*. 2019 Jun;8(2):70..
12. Beauchemin C, Guinan K, Claveau D, Dufresne SF, Rotstein C. Economic evaluation of isavuconazole for suspected invasive pulmonary aspergillosis in Canada. *Expert review of pharmacoeconomics & outcomes research*. 2021 Sep 26:1-0.
13. Bowler PG, Duerden BI, Armstrong DG. Wound microbiology and associated approaches to wound management. *Clinical microbiology reviews*. 2001 Apr 1;14(2):244-69.
14. Barros MB, de Almeida Paes R, Schubach AO. *Sporothrix schenckii* and Sporotrichosis. *Clinical microbiology reviews*. 2011 Oct;24(4):633-54.
15. Samanta I. Cutaneous, Subcutaneous and Systemic Mycology. *Veterinary Mycology* [Internet]. 2015 [cited 2021 Oct 25];11. Available from: /pmc/articles/PMC7122059/
16. Mayer FL, Wilson D, Hube B. *Candida albicans* pathogenicity mechanisms. *Virulence*. 2013 Feb 15;4(2):119-28.
17. Manju M, Ghosh A, Pal R, Quiñones-Ossa GA, Mohan R, Agrawal A. Principles and practices of biosafety: Expanding and extending to food safety and food supply chain. *Environmental Disease*. 2021 Apr 1;6(2):31.
18. Vautier S, Drummond RA, Chen K, Murray GI, Kadosh D, Brown AJ, Gow NA, MacCallum DM, Kolls JK, Brown GD. *Candida albicans* colonization and dissemination from the murine gastrointestinal tract: the influence of morphology and T h17 immunity. *Cellular microbiology*. 2015 Apr;17(4):445-50.
19. Boland JM, Chung HH, Robberts FJL, Wilson WR, Steckelberg JM, Baddour LM, et al. Fungal prosthetic valve endocarditis: Mayo Clinic experience with a clinicopathological analysis. *Mycoses*. 2011 Jul;54(4):354–60.
20. Yusuf E. A Book Review on: Sherris Medical Microbiology–International Edition. *Frontiers in Cellular and Infection Microbiology*. 2015 Apr 10;5:34.
21. Jacysyn JF, Abrahamsohn IA, Macedo MS. Modulation of delayed-type hypersensitivity during the time course of immune response to a protein antigen. *Immunology*. 2001 Mar;102(3):373-9.
22. Sathyan G, Ritschel WA, Hussain AS. Transdermal delivery of tacrine: I. Identification of a suitable delivery vehicle. *International journal of pharmaceutics*. 1995 Jan 31;114(1):75-83.
23. Shah RR, Magdum CS, Wadkar KA, Naikwade NS. Fluconazole topical microemulsion: preparation and evaluation. *Research Journal of Pharmacy and Technology*. 2009;2(2):353-7.
24. Banerjee M, Ghosh AK, Basak S, Das KD, Gangopadhyay N. Comparative evaluation of efficacy and safety of topical fluconazole and clotrimazole in the treatment of tinea corporis. *Journal of Pakistan Association of Dermatologists*. 2012 Oct 1;22(4).
25. Khatoon Z, McTiernan CD, Suuronen EJ, Mah TF, Alarcon EI. Bacterial biofilm formation on implantable devices and approaches to its treatment and prevention. *Heliyon*. 2018 Dec 1;4(12):e01067.

26. Costa-Orlandi CB, Sardi JC, Pitangui NS, De Oliveira HC, Scorzoni L, Galeane MC, Medina-Alarcón KP, Melo WC, Marcelino MY, Braz JD, Fusco-Almeida AM. Fungal biofilms and polymicrobial diseases. *Journal of Fungi*. 2017 Jun;3(2):22.
27. Ramage G, Saville SP, Thomas DP, Lopez-Ribot JL. Candida biofilms: an update. *Eukaryotic cell*. 2005 Apr;4(4):633-8.
28. López-Ribot JL. Candida albicans biofilms: More than filamentation. *Current Biology*. 2005 Jun 21;15(12).
29. Stone NR, Bicanic T, Salim R, Hope W. Liposomal amphotericin B (AmBisome®): a review of the pharmacokinetics, pharmacodynamics, clinical experience and future directions. *Drugs*. 2016 Mar 1;76(4):485-500.
30. Normark S, Schönebeck J. In vitro studies of 5-fluorocytosine resistance in Candida albicans and Torulopsis glabrata. *Antimicrobial Agents and Chemotherapy*. 1972 Sep;2(3):114-21.
31. Garg A, Sharma GS, Goyal AK, Ghosh G, Si SC, Rath G. Recent advances in topical carriers of anti-fungal agents. *Heliyon*. 2020 Aug 1;6(8):e04663.
32. Meis JF, Chowdhary A, Rhodes JL, Fisher MC, Verweij PE. Clinical implications of globally emerging azole resistance in Aspergillus fumigatus. *Philosophical Transactions of the Royal Society B: Biological Sciences*. 2016 Dec 5;371(1709):20150460.
33. Capela R, Moreira R, Lopes F. An overview of drug resistance in protozoal diseases. *International journal of molecular sciences*. 2019 Jan;20(22):5748.
34. Beardsley J, Halliday CL, Chen SC, Sorrell TC. Responding to the emergence of antifungal drug resistance: perspectives from the bench and the bedside. *Future microbiology*. 2018 Aug;13(10):1175-91.
35. Uchechi O, Ogbonna JD, Attama AA. Nanoparticles for dermal and transdermal drug delivery. *Application of nanotechnology in drug delivery*. 2014 Jul 25;4:193-227.
36. Bhatt P, Lalani R, Vhora I, Patil S, Amrutiya J, Misra A, Mashru R. Liposomes encapsulating native and cyclodextrin enclosed paclitaxel: Enhanced loading efficiency and its pharmacokinetic evaluation. *International journal of pharmaceutics*. 2018 Jan 30;536(1):95-107.
37. Mishra V, Bansal KK, Verma A, Yadav N, Thakur S, Sudhakar K, Rosenholm JM. Solid lipid nanoparticles: Emerging colloidal nano drug delivery systems. *Pharmaceutics*. 2018 Dec;10(4):191.
38. Naseri N, Valizadeh H, Zakeri-Milani P. Solid lipid nanoparticles and nanostructured lipid carriers: structure, preparation and application. *Advanced pharmaceutical bulletin*. 2015 Sep;5(3):305.
39. Mukherjee S, Ray S, Thakur RS. Solid lipid nanoparticles: a modern formulation approach in drug delivery system. *Indian journal of pharmaceutical sciences*. 2009 Jul;71(4):349.
40. Gardouh AR, Faheim SH, Noah AT, Ghorab MM. Influence of formulation factors on the size of nanostructured lipid carriers and nanoemulsions prepared by high shear homogenization. *International journal of pharmacy and pharmaceutical sciences*. 2018 Apr 1:61-75.

41. Abdulredha MM, Siti Aslina H, Luqman CA. Overview on petroleum emulsions, formation, influence and demulsification treatment techniques. *Arabian Journal of Chemistry*. 2020 Jan 1;13(1):3403–28.
42. Duan Y, Dhar A, Patel C, Khimani M, Neogi S, Sharma P, Kumar NS, Vekariya RL. A brief review on solid lipid nanoparticles: Part and parcel of contemporary drug delivery systems. *RSC Advances*. 2020;10(45):26777-91.
43. Puri A, Loomis K, Smith B, Lee JH, Yavlovich A, Heldman E, Blumenthal R. Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic. *Critical Reviews™ in Therapeutic Drug Carrier Systems*. 2009;26(6).
44. Chauhan I, Yasir M, Verma M, Singh AP. Nanostructured lipid carriers: A groundbreaking approach for transdermal drug delivery. *Advanced pharmaceutical bulletin*. 2020 Jun;10(2):150.
45. Saini N, Arora V, Gupta N. SOLID LIPID NANOPARTICLES FOR ANTIFUNGAL DRUG DELIVERY SYSTEM.
46. Suttiponparnit K, Jiang J, Sahu M, Suvachittanont S, Charinpanitkul T, Biswas P. Role of surface area, primary particle size, and crystal phase on titanium dioxide nanoparticle dispersion properties. *Nanoscale Res Lett*. 2011 Dec;6(1):1-8.
47. Rathor S, Bhatt DC, Aamir S, Singh SK, Kumar V. A comprehensive review on role of nanoparticles in therapeutic delivery of medicine. *Pharmaceutical nanotechnology*. 2017 Dec 1;5(4):263-75.
48. Aboofazeli R, Barlow DJ, Lawrence MJ. Particle size analysis of concentrated phospholipid microemulsions: II. Photon correlation spectroscopy. *Aaps Pharmsci*. 2000 Sep;2(3):1-0.
49. Smith MC, Crist RM, Clogston JD, McNeil SE. Zeta potential: a case study of cationic, anionic, and neutral liposomes. *Analytical and bioanalytical chemistry*. 2017 Sep;409(24):5779-87.
50. Khosa A, Reddi S, Saha RN. Nanostructured lipid carriers for site-specific drug delivery. *Biomedicine & Pharmacotherapy*. 2018 Jul 1;103:598–613.
51. Karoui R. Food Authenticity and Fraud. *Chemical Analysis of Food: Techniques and Applications*. 2012;499–517.
52. Jannin V, Musakhanian J, Marchaud D. Approaches for the development of solid and semi-solid lipid-based formulations. *Advanced Drug Delivery Reviews*. 2008 Mar 17;60(6):734–46.
53. Schwab L, Allain P, Mauran N, Dollat X, Mazonq L, Lagrange D, Gély M, Hentz S, Jourdan G, Favero I, Legrand B. Very high frequency probes for atomic force microscopy with silicon optomechanics. *arXiv preprint arXiv:2109.02478*. 2021 Aug 27.
54. Last JA, Russell P, Nealey PF, Murphy CJ. The applications of atomic force microscopy to vision science. *Investigative ophthalmology & visual science*. 2010 Dec 1;51(12):6083-94.
55. Salamanca CH, Barrera-Ocampo A, Lasso JC, Camacho N, Yarce CJ. Franz diffusion cell approach for pre-formulation characterisation of ketoprofen semi-solid dosage forms. *Pharmaceutics*. 2018 Sep;10(3):148.

56. Tiwari G, Tiwari R, Sriwastawa B, Bhati L, Pandey S, Pandey P, Bannerjee SK. Drug delivery systems: An updated review. *International journal of pharmaceutical investigation*. 2012 Jan;2(1):2.
57. Mishra V, Bansal KK, Verma A, Yadav N, Thakur S, Sudhakar K, Rosenholm JM. Solid lipid nanoparticles: Emerging colloidal nano drug delivery systems. *Pharmaceutics*. 2018 Dec;10(4):191.
58. Williams A. *Transdermal and topical drug delivery from theory to clinical practice*. Pharmaceutical Press; 2003.
59. Guy RH. Current status and future prospects of transdermal drug delivery. *Pharmaceutical research*. 1996 Dec;13(12):1765-9.
60. Kakkar S, Karuppayil SM, Raut JS, Giansanti F, Papucci L, Schiavone N, Kaur IP. Lipid-polyethylene glycol based nano-ocular formulation of ketoconazole. *International journal of pharmaceutics*. 2015 Nov 10;495(1):276-89.
61. Souto EB, Wissing SA, Barbosa CM, Müller RH. Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery. *International journal of pharmaceutics*. 2004 Jun 18;278(1):71-7.
62. Paolicellia P, Correntea F, Serricchioa D, Cerretoa F, Cesaa S, Titab B. The system SLN-Dextran hydrogel: An application for the topical delivery of ketoconazole. *J Chem Pharm Res*. 2011;3(4):410-21.
63. Sanna V, Gavini E, Cossu M, Rassu G, Giunchedi P. Solid lipid nanoparticles (SLN) as carriers for the topical delivery of econazole nitrate: in-vitro characterization, ex-vivo and in-vivo studies. *Journal of pharmacy and pharmacology*. 2007 Aug;59(8):1057-64.
64. Passerini N, Gavini E, Albertini B, Rassu G, Di Sabatino M, Sanna V, Giunchedi P, Rodriguez L. Evaluation of solid lipid microparticles produced by spray congealing for topical application of econazole nitrate. *Journal of Pharmacy and Pharmacology*. 2009 May;61(5):559-67.
65. Cassano R, Ferrarelli T, Mauro MV, Cavalcanti P, Picci N, Trombino S. Preparation, characterization and in vitro activities evaluation of solid lipid nanoparticles based on PEG-40 stearate for antifungal drugs vaginal delivery. *Drug delivery*. 2016 Mar 23;23(3):1037-46.
66. Ghasemiyeh P, Mohammadi-Samani S. Solid lipid nanoparticles and nanostructured lipid carriers as novel drug delivery systems: applications, advantages and disadvantages. *Research in pharmaceutical sciences*. 2018 Aug;13(4):288.
67. Attama AA, Momoh MA, Builders PF. Lipid nanoparticulate drug delivery systems: a revolution in dosage form design and development. *Recent advances in novel drug carrier systems*. 2012 Oct 31;5:107-40.
68. Pavlou P, Siamidi A, Varvaresou A, Vlachou M. Skin Care Formulations and Lipid Carriers as Skin Moisturizing Agents. *Cosmetics*. 2021 Sep;8(3):89.
69. Vieira D.B., Carmona-Ribeiro A.M. Cationic lipids and surfactants as antifungal agents: mode of action. *J. Antimicrob. Chemother.* 2006 Aug 2;58(4):760–767.
70. Karami Z., Hamidi M. Cubosomes: remarkable drug delivery potential. *Drug Discov. Today*. 2016 May 1;21(5):789–801.

71. Souto E.B., Müller R.H. The use of SLN® and NLC® as topical particulate carriers for imidazole antifungal agents. *Die Pharmazie-An Int J Pharmaceutical Sci.* 2006 May 1;61(5):431–437.
72. Gratieri T, Krawczyk-Santos AP, da Rocha PB, Gelfuso GM, Marreto RN, Taveira SF. SLN- and NLC-encapsulating antifungal agents: skin drug delivery and their unexplored potential for treating onychomycosis. *Current pharmaceutical design.* 2017 Dec 1;23(43):6684-95.
73. El-Housiny S, Eldeen MAS, El-Attar YA, Salem HA, Attia D, Bendas ER, et al. Fluconazole-loaded solid lipid nanoparticles topical gel for treatment of pityriasis versicolor: formulation and clinical study. *Drug Delivery [Internet].* 2018 [cited 2021 Oct 26];25(1):78.
74. Dudhipala N, Ay AA. Amelioration of ketoconazole in lipid nanoparticles for enhanced antifungal activity and bioavailability through oral administration for management of fungal infections. *Chemistry and Physics of Lipids.* 2020 Oct 1;232:104953.
75. Carbone C, Fuocho V, Zielińska A, Musumeci T, Souto EB, Bonaccorso A, Puglia C, Petronio GP, Furneri PM. Dual-drugs delivery in solid lipid nanoparticles for the treatment of *Candida albicans* mycosis. *Colloids and Surfaces B: Biointerfaces.* 2020 Feb 1;186:110705.
76. Kraisit P, Hirun N, Mahadlek J, Limmatvapirat S. Fluconazole-loaded solid lipid nanoparticles (SLNs) as a potential carrier for buccal drug delivery of oral candidiasis treatment using the Box-Behnken design. *Journal of Drug Delivery Science and Technology.* 2021 Jun 1;63:102437.
77. Passos JS, de Martino LC, Dartora VF, de Araujo GL, Ishida K, Lopes LB. Development, skin targeting and antifungal efficacy of topical lipid nanoparticles containing itraconazole. *European Journal of Pharmaceutical Sciences.* 2020 Jun 15;149:105296.
78. Na YG, Huh HW, Kim MK, Byeon JJ, Han MG, Lee HK, Cho CW. Development and evaluation of a film-forming system hybridized with econazole-loaded nanostructured lipid carriers for enhanced antifungal activity against dermatophytes. *Acta biomaterialia.* 2020 Jan 1;101:507-18.
79. Alhakamy NA, Md S, Alam MS, Shaik RA, Ahmad J, Ahmad A, Kutbi HI, Noor AO, Bagalagel A, Bannan DF, Gorain B. Development, Optimization, and Evaluation of Luliconazole Nanoemulgel for the Treatment of Fungal Infection. *Journal of Chemistry.* 2021 Nov 5;2021.
80. Elkomy MH, Elmowafy M, Shalaby K, Azmy AF, Ahmad N, Zafar A, Eid HM. Development and machine-learning optimization of mucoadhesive nanostructured lipid carriers loaded with fluconazole for treatment of oral candidiasis. *Drug Development and Industrial Pharmacy.* 2021 Feb 1;47(2):246-58.
81. Mahmood A, Rapalli VK, Gorantla S, Waghule T, Singhvi G. Dermatokinetic assessment of luliconazole-loaded nanostructured lipid carriers (NLCs) for topical delivery: QbD-driven design, optimization, and in vitro and ex vivo evaluations. *Drug Delivery and Translational Research.* 2021 Apr 24:1-8.
82. Kamble MS, Vaidya KK, Bhosale AV, Chaudhari PD. Solid lipid nanoparticles and nanostructured lipid carriers—an overview. *Int J Pharm Chem Biol Sci.* 2012;2(4):681-91.

83. Parhi R, Suresh P. Production of solid lipid nanoparticles-drug loading and release mechanism. J Chem Pharm Res. 2010;2(1):211-7.

84. <https://clinicaltrials.gov/>

UNDER PEER REVIEW